Hana given outperform by RBC

Hana Biosciences, Inc. was rated by RBC Capital Markets analyst David Bouchey at outperform, speculative risk. Both Talotrexin and Zensana pharmacologic data at the American Society for Clinical Oncology annual meeting look good, according to the analyst. A near-term filing under the 505b2 pathway and launch by mid-2007 is expected. Shares of the South San Francisco, Calif.-based biopharmaceutical company were down $0.04, or 0.43%, at $9.19 on volume of 87,623 shares versus the three-month running average of 198,849shares. (Nasdaq: HNAB)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.